However, the top three Grade 3 or 4 non-hematological AEs in the monotherapy of twelve BET inhibitors were pneumonia (7.5%), elevated bilirubin (5.1%), and fatigue (4.7%) (Figures 3C,D). This evidence concerns the gene DNER and pneumonia.